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Acute myeloid leukemia (AML) is a 
blood cancer characterized by uncon-
trolled proliferation of myeloid progeni-
tors that exhibit a severe block in their 
ability to differentiate into mature granu-
locytes or macrophages. A critical event 
in AML initiation is the acquisition of ab-
errant self-renewal characteristics in leu-
kemia stem cells (LSCs), a cell population 
that has been associated with disease 
propagation and the evolution of therapy-
resistance. The estimated 5 yr survival 
rate among AML patients is 30%, with 
mortality being largely attributed to the 
emergence of chemotherapy resistance. 
Deregulated transcriptional pathways fea-
ture prominently in the genetic etiology 
of AML, which can occur in the form 
of gain- or loss-of-function mutations 
in lineage-specific transcription factors, 
histone modifying enzymes, and DNA 
methylation machineries (Rosenbauer 
and Tenen, 2007; Shih et al., 2012). Of 
clinical relevance, pharmacological tar-
geting of transcriptional regulatory pro-
teins represents a validated approach for 
undermining the driver oncogenes in 
certain subtypes of AML, as exemplified 
by the clinical success of using all-trans 
retinoic acid and arsenic trioxide to inac-
tivate fusion oncoproteins involving the 
retinoic acid receptor (Wang and Chen, 
2008; Ablain et al., 2013).
One important genetic subtype of 
AML is defined by rearrangements of 
the mixed lineage leukemia (MLL) gene, 
which is found in 5% of patients 
(Krivtsov and Armstrong, 2007). MLL 
encodes a histone-modifying enzyme 
belonging to the SET1 family of H3 ly-
sine 4 (H3K4) methyltransferases, which 
often function as transcriptional coacti-
vators (Shilatifard, 2012). In AML, chro-
mosomal translocations can involve MLL 
and various other genes, of which >50 
partner loci have been described to date 
(Krivtsov and Armstrong, 2007). Some 
of the most common translocation part-
ners of MLL include AF9, ENL, AF4, 
AF6, AF10, and ELL. The in-frame fu-
sion of the N terminus of MLL with the 
C terminus of its fusion partner leads to 
the formation of a potent oncoprotein 
(e.g., MLL-ENL) that can efficiently 
transform hematopoietic stem and pro-
genitor cells. This genetic driver that has 
been widely used to generate animal 
models of leukemia for studying all as-
pects of disease biology, including LSC 
specification and chemotherapy resis-
tance (Krivtsov et al., 2006; Somervaille 
and Cleary, 2006; Zuber et al., 2009). 
MLL-rearranged leukemia is considered 
a poor/intermediate prognosis subtype 
of leukemia for which targeted therapies 
have yet to make any clinical impact 
(Krivtsov and Armstrong, 2007).
Mechanistically, MLL fusion proteins 
form hybrid multisubunit protein com-
plexes that include factors associated 
with the MLL N-terminal fragment 
(Menin, LEDGF, and PAF1) and fac-
tors associated with the fusion partner 
C-terminal fragment (Mohan et al., 
2010). Remarkably, many of the com-
mon C-terminal fusion partners associ-
ate with one another in a complex that 
includes the protein kinase pTEFb and 
the histone methyltransferase DOT1L, 
which act as effectors to promote tran-
scription elongation (Okada et al., 2005; 
Lin et al., 2010; Yokoyama et al., 2010). 
Because MLL fusion proteins lack the 
domains required for catalysis of H3K4 
methylation, they instead rely on the 
C-terminal fusion partner to recruit 
pTEFb and DOT1L to promote tran-
scriptional activation of their target genes 
(Okada et al., 2005). Among the well-
validated direct targets of MLL fusion 
proteins are genes encoding homeodo-
main-containing transcription factors, 
including Hoxa9 and Meis1 (Armstrong 
et al., 2002). Forced co-overexpression 
of Hoxa9 and Meis1 can itself efficiently 
transform hematopoietic cells and form 
leukemias that resemble those initiated 
by MLL fusion proteins (Kroon et al., 
1998). In addition to Hoxa9/Meis1, MLL 
fusion proteins also activate the expres-
sion of numerous additional transcrip-
tion factor–encoding genes, such as Myc, 
Myb, and Mef2c, which are crucial for 
disease maintenance (Krivtsov et al., 2006; 
Zuber et al., 2011a). Furthermore, MLL 
fusion leukemia cells are also dependent 
on chromatin regulatory activities to 
maintain a transformed cellular state, such 
as the histone demethylase LSD1 and the 
BET protein BRD4 (Zuber et al., 2011b; 
Harris et al., 2012). Thus, MLL-rearranged 
Acute myeloid leukemia (AML) is a hematopoietic malignancy characterized 
by clonal expansion of myeloid progenitor cells. A major mechanistic theme 
in AML biology is the extensive collaboration among fusion oncoproteins, 
transcription factors, and chromatin regulators to initiate and sustain a 
transformed cellular state. A new study in this issue describes how the C/EBP 
transcription factor is crucial for the initiation of AML induced by MLL 
fusion oncoproteins, but is entirely dispensable for the maintenance of estab-
lished disease. These observations provide a unique glimpse into the pioneer 
round of regulatory events that are critical at the origin of AML formation. 
Furthermore, this study implies the existence of oncogene-induced positive 
feedback loops capable of bypassing the continuous need for certain regula-
tors to propagate disease.
J.S. Roe and C.R. Vakoc are at the Cold Spring Harbor 
Laboratory, Cold Spring Harbor, NY 11724.
CORRESPONDENCE  
C.R.V.: vakoc@cshl.edu
C/EBP: critical at the origin of leukemic transformation
Jae-Seok Roe and Christopher R. Vakoc
© 2014 Roe and Vakoc This article is distributed under the terms of 
an Attribution–Noncommercial–Share Alike–No Mirror Sites license 
for the first six months after the publication date (see http://www 
.rupress.org/terms). After six months it is available under a Crea-
tive Commons License (Attribution–Noncommercial–Share Alike 3.0 
Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
T
h
e 
Jo
u
rn
al
 o
f 
E
xp
er
im
en
ta
l 
M
ed
ic
in
e
 o
n
 January 22, 2014
jem.rupress.org
D
ow
nloaded from
 
Published January 6, 2014
 C/EBP is critical at the origin of leukemic transformation | Roe and Vakoc
leukemogenesis, Ohlsson et al. (2013) 
noted that C/EBP target genes tended 
to be more highly expressed in MLL-
rearranged human AML samples when 
compared with normal hematopoietic 
progenitors. To determine the functional 
relevance of this observation, the authors 
evaluated whether C/EBP knockout 
hematopoietic stem and progenitor cells 
were capable of being transformed by 
the MLL-ENL oncogene. Importantly, 
in this experimental design they first 
inactivated C/EBP in vivo with con-
ditional alleles, followed by retroviral 
transduction of MLL-ENL into the he-
matopoietic stem and progenitor cells 
isolated from these animals. The authors 
found that C/EBP was absolutely es-
sential for MLL-ENL–mediated trans-
formation in colony formation assays, 
liquid culture, and after transplantation 
in vivo. Based on prior studies (such as the 
aforementioned BCR-ABL study), this 
result was not entirely surprising. C/EBP 
is critical in the formation of normal 
GMPs, and thus a failure to form myeloid 
lineage leukemias may simply reflect the 
normal lineage requirement for C/EBP 
in myeloid progenitors. To address this, 
the authors first sorted GMPs from 
C/EBPfloxed/floxed mice and subsequently 
inactivated C/EBP, since upon reaching 
the GMP stage C/EBP has been shown 
to be dispensable for further myeloid 
maturation (Zhang et al., 2004). Impor-
tantly, C/EBP-null GMP cells were still 
unable to be transformed by MLL-ENL, 
suggesting an intrinsic requirement for 
C/EBP that is independent of lin-
eage establishment (Ohlsson et al., 2013). 
C/EBP-knockout cells also failed to be 
transformed by co-transduction with 
Hoxa9/Meis1, indicating that a defect 
in MLL-ENL–mediated activation of 
these two downstream target genes was 
not the primary cause of impaired leuke-
mogenesis. This finding also suggests that 
the C/EBP requirement is not re-
stricted to MLL fusion AML, but ap-
plies to other oncogenes that activate 
related pathways. However, C/EBP  
is not required for transformation in-
duced by the E2A-HLF oncogene, 
demonstrating that C/EBP is only re-
quired for leukemogenesis in specific 
genetic contexts.
progenitor (GMP) stage of differentiation 
and leads to enhanced self-renewal of he-
matopoietic stem cells, highlighting the 
essential function of C/EBP for nor-
mal hematopoiesis (Zhang et al., 2004).
Genetic alteration of C/EBP is a 
major etiology of human AML, with a 
mutational frequency 10% across this 
disease (Pabst et al., 2001b). C/EBP 
mutations fall into two major categories: 
those that abolish p42 protein expression 
while retaining p30 and insertions/ 
deletions near the BR-LZ region that 
compromise DNA binding, which may 
result in dominant-negative homodi-
mers or heterodimers with other C/EBP 
family members (Nerlov, 2004). Interest-
ingly, these two classes of mutations often 
co-occur in a biallelic manner in AML 
patients. C/EBP expression can also be 
down-regulated through direct transcrip-
tional repression by fusion oncoproteins, 
such as AML1-ETO (Pabst et al., 2001a). 
A selective knockout of p42 in mice 
(while preserving p30 expression) leads 
to AML formation with complete pen-
etrance, confirming the p42 isoform of 
C/EBP as a myeloid tumor suppressor 
gene (Kirstetter et al., 2008). Null muta-
tions of C/EBP that abolish both p42 
and p30 are not observed in human AML, 
and mice with a complete knockout of 
p42/p30 fail to develop AML, suggesting 
that residual C/EBP function (presum-
ably via the p30 isoform) is necessary to 
form myeloid lineage leukemias (Zhang 
et al., 2004). Consistent with this possi-
bility, C/EBP knockout bone marrow 
will not form myeloid leukemias when 
transduced with BCR-ABL, but instead 
will only form leukemias of the eryth-
roid lineage in this genetic background 
(Wagner et al., 2006). These results high-
light a critical dosage-dependent role of 
C/EBP in AML pathogenesis: partial 
loss of function (e.g., through selective loss 
of p42) can drive AML progression whereas 
complete loss (e.g., through complete loss 
of p30/42) might be incompatible with 
leukemias of the myeloid lineage.
C/EBP is essential for the initiation 
but not the maintenance of MLL 
fusion leukemia
In an effort to discover novel transcription 
factors that support MLL fusion-mediated 
leukemia is a paradigm for understand-
ing how a vast network of transcriptional 
regulators cooperates to sustain an aber-
rant lineage program. A new study in this 
issue of the JEM, Ohlsson et al., demon-
strates an essential collaboration between 
MLL fusion proteins and the transcrip-
tion factor C/EBP during leukemo-
genesis. Interestingly, C/EBP is critical 
for the initiation of MLL fusion leuke-
mia but becomes dispensable once the 
disease is fully established.
Function of C/EBP in normal  
and malignant myelopoiesis
The CCAAT/enhancer-binding pro-
tein- (C/EBP) is a lineage-specific 
transcription factor in the hematopoietic 
system that is required for the formation 
of committed myeloid progenitors from 
multipotent precursor cells (Rosenbauer 
and Tenen, 2007). C/EBP executes this 
function by coupling the direct tran-
scriptional activation of myeloid-specific 
genes with the arrest of cell proliferation 
(Nerlov, 2004). C/EBP belongs to a 
subfamily of basic-region leucine zipper 
(BR-LZ) transcription factors, several of 
which are also expressed in the myeloid 
lineage (e.g., C/EBP and C/EBP; 
Rosenbauer and Tenen, 2007). C/EBP 
is an intronless gene whose mRNA can 
be translated from two different AUG 
codons to give rise to two distinct iso-
forms (p42 and p30). p30 lacks two 
N-terminal trans-activation domains that 
are only present on p42. Notably, this 
unique N-terminal region of p42 can in-
teract with and inhibit E2F transcription 
factors (Slomiany et al., 2000; Porse et al., 
2001). Hence, only the p42 isoform of 
C/EBP can promote proliferation ar-
rest. p30 retains the BR-LZ and a third 
trans-activation domain and can promote 
myeloid lineage specification, but lacks the 
capacity to promote terminal differentia-
tion and proliferation-arrest (Kirstetter 
et al., 2008). The relative levels of p42 
and p30 in the cell can be regulated at 
the level of translation initiation through 
mTOR signaling to control cell fate tran-
sitions (Calkhoven et al., 2000). Notably, 
a genetic knockout C/EBP (p30 and 
p42) results in a complete block in the 
transition from common myeloid progen-
itor (CMP) to the granulocyte/monocyte 
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positive feedback loop (Fig. 1). Myb has 
previously been shown to physically as-
sociate with MLL fusion proteins and 
would be a logical candidate for bypass-
ing the C/EBP requirement for onco-
protein recruitment to DNA (Jin et al., 
2010). Other C/EBP family homologues 
(e.g., C/EBP) expressed in fully trans-
formed MLL fusion leukemia cells would 
be additional candidates that could al-
leviate the C/EBP requirement after 
leukemic transformation. An alternative 
explanation for a transient C/EBP re-
quirement could be that MLL fusion 
proteins regulate distinct genes at differ-
ent temporal stages of leukemic trans-
formation. In this situation, C/EBP is 
Open questions
Perhaps the most provocative question 
raised by this study is why C/EBP  
becomes dispensable after full leukemic 
transformation. Although this issue was 
not directly addressed in this study, one 
can envision several regulatory scenarios 
that could explain this result. MLL fu-
sion proteins are known to induce the 
expression of numerous additional tran-
scription factors (e.g., Myb, Mef2c, Myc; 
Zuber et al., 2011a). These transcription 
factors, once achieving high levels of 
expression in transformed cells, might 
themselves be capable of stabilizing MLL 
fusion protein recruitment to chromatin, 
thereby establishing an oncogene-induced 
Extending these observations to the 
setting of disease maintenance, Ohlsson 
et al. (2013) went on to evaluate whether 
conditional inactivation of C/EBP after 
MLL-ENL transduction also impaired 
cell expansion. Remarkably, conditional 
inactivation of C/EBP in MLL-ENL–
transformed cells had no effect on colony 
formation in serial replating assays or 
under in vivo conditions. C/EBP-null 
AML could also be readily transplanted 
into tertiary recipients without any delay 
in disease progression, highlighting the 
dispensability of C/EBP in leukemia 
stem cell subpopulations. These find-
ings provide a dramatic example where a 
gene can be required exclusively at the 
stage of cancer initiation but is rendered 
superfluous in the setting of a fully trans-
formed state.
What could be the mechanistic 
basis for the C/EBP-requirement for 
leukemia initiation? Ohlsson et al. (2013) 
found that the majority of genes in-
duced immediately after MLL-ENL 
transduction were not properly induced 
in C/EBP-null cells. Furthermore, 
ChIP-seq analysis revealed that C/EBP 
binding to DNA correlates with MLL-
ENL target genes. These observations 
suggest, although do not prove, that 
C/EBP binding to DNA might be a 
prerequisite for MLL fusion proteins 
to efficiently occupy chromatin during 
the initial stages of leukemogenesis. 
Such a model, however, cannot explain 
why C/EBP is also required for initi-
ation of AML by Hoxa9/Meis1 over-
expression, since these cells lack an 
MLL fusion protein. It is interesting 
to note that a prior ChIP-seq analysis 
performed in leukemia cells found a 
close correlation between C/EBP and 
Hoxa9/Meis1-binding sites at a large 
number of distal enhancer elements 
(Huang et al., 2012). This observation 
raises the interesting possibility that 
C/EBP might also prime chromatin 
for subsequent binding of Hoxa9/Meis1 
proteins at regulatory elements. Such 
a function would be reminiscent of 
pioneer transcription factors, described 
previously as a class of DNA-binding 
proteins that render chromatin com-
petent for other factors to bind (Zaret 
and Carroll, 2011).
Figure . A speculative model to account for a transient C/EBP requirement during ini-
tiation of MLL-ENL– or Hoxa9/Meis-induced acute myeloid leukemia. (top) At the onset of 
oncoprotein expression, C/EBP is critical for initial recruitment of MLL-ENL or Hoxa9/Meis1 to their 
target sites on DNA, as depicted by arrows pointing from C/EBP to these factors. Such an effect 
could be mediated through direct physical interactions or indirectly by increasing DNA accessibility. 
Many of the known target genes of MLL-ENL and Hoxa9/Meis1 are other transcription factors (TFs), 
hence C/EBP would be critical to drive the initial burst in expression of these factors. (bottom) 
Upon reaching a fully transformed state, these additional TFs (encoded by genes up-regulated by the 
oncoproteins) would now have achieved sufficient levels of expression to participate in stabilizing 
oncoprotein recruitment. In this situation, they might act in parallel with (or replace) C/EBP at  
MLL-ENL– or Hoxa9/Meis1-binding sites. In this fully transformed state, the C/EBP requirement 
would be alleviated by these alternative TFs.
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critical for the primary wave of regula-
tory events that occur upon leukemia 
initiation, but becomes dispensable as dis-
ease progresses; as MLL-ENL occupancy 
on chromatin shifts to a secondary set 
of target genes that are regulated in a 
C/EBP-independent manner. Elucidat-
ing the mechanistic basis for the transient 
role of C/EBP during AML progres-
sion will be a worthwhile endeavor and 
may redefine our understanding of the 
stepwise progression of leukemogenesis.
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